A bullish thesis on Moderna, Inc. (MRNA) by Natan highlights its transformative potential in mRNA technology despite challenges. Moderna's tech-driven approach, robust drug pipeline, and revenue from COVID-19 vaccines position it for significant growth, supported by insider confidence and global infrastructure investments.